tradingkey.logo

Revelation Biosciences Inc

REVB
0.893USD
-0.008-0.87%
Close 12/19, 16:00ETQuotes delayed by 15 min
3.20MMarket Cap
0.01P/E TTM

Revelation Biosciences Inc

0.893
-0.008-0.87%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Revelation Biosciences Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Revelation Biosciences Inc's Score

Industry at a Glance

Industry Ranking
296 / 501
Overall Ranking
542 / 4682
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
21.250
Target Price
+1914.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Revelation Biosciences Inc Highlights

StrengthsRisks
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is 0.01, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 75.14K shares, increasing 44.72% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

No financial score is currently available for Revelation Biosciences Inc. The Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score
0.00
Change
0

Financials

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

Operational Efficiency

Growth Potential

Shareholder Returns

Revelation Biosciences Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The current valuation score of Revelation Biosciences Inc is 7.22, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.01, which is 13394.00% below the recent high of 2.02 and 194034.67% above the recent low of -29.09.

Score

Industry at a Glance

Previous score
7.22
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 296/501
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-10-27

The current earnings forecast score of Revelation Biosciences Inc is 8.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The average price target for Revelation Biosciences Inc is 21.25, with a high of 22.50 and a low of 20.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
21.250
Target Price
+1914.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Revelation Biosciences Inc
REVB
1
CRISPR Therapeutics AG
CRSP
30
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The current price momentum score of Revelation Biosciences Inc is 1.13, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.60 and the support level at 1.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
1.13
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.002
Sell
RSI(14)
37.620
Neutral
STOCH(KDJ)(9,3,3)
8.772
Oversold
ATR(14)
0.094
High Vlolatility
CCI(14)
-127.308
Sell
Williams %R
90.353
Oversold
TRIX(12,20)
-0.062
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.933
Sell
MA10
1.007
Sell
MA20
0.970
Sell
MA50
1.074
Sell
MA100
1.617
Sell
MA200
3.897
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The current institutional shareholding score of Revelation Biosciences Inc is 3.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.21%, representing a quarter-over-quarter decrease of 52.82%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Armistice Capital LLC
46.79K
+371.84%
Rolke (James M)
10.05K
--
Zygmont (Chester Stanley III)
5.03K
+0.02%
Sabby Management, LLC
21.93K
--
Carver (Jennifer A)
63.00
+1.61%
Roper (Jess)
61.00
--
Chawla (Lakhmir S)
61.00
+1.67%
Geode Capital Management, L.L.C.
--
-100.00%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-27

No risk assessment score is currently available for Revelation Biosciences Inc. The Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
0.00
Change
0
Beta vs S&P 500 index
-0.16
VaR
+11.71%
240-Day Maximum Drawdown
+91.85%
240-Day Volatility
+186.98%

Return

Best Daily Return
60 days
+11.14%
120 days
+15.35%
5 years
+101.21%
Worst Daily Return
60 days
-8.70%
120 days
-19.03%
5 years
-63.87%
Sharpe Ratio
60 days
-3.09
120 days
-1.91
5 years
-1.16

Risk Assessment

Maximum Drawdown
240 days
+91.85%
3 years
+99.97%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.99
3 years
-0.33
5 years
-0.20
Skewness
240 days
-1.53
3 years
+1.11
5 years
+2.09

Volatility

Realised Volatility
240 days
+186.98%
5 years
--
Standardised True Range
240 days
+37.57%
5 years
+572187.06%
Downside Risk-Adjusted Return
120 days
-246.03%
240 days
-246.03%
Maximum Daily Upside Volatility
60 days
+59.92%
Maximum Daily Downside Volatility
60 days
+49.25%

Liquidity

Average Turnover Rate
60 days
+35.43%
120 days
+147.72%
5 years
--
Turnover Deviation
20 days
-99.56%
60 days
-98.30%
120 days
-92.92%

Peer Comparison

Biotechnology & Medical Research
Revelation Biosciences Inc
Revelation Biosciences Inc
REVB
3.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Revelation Biosciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Revelation Biosciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Revelation Biosciences Inc’s performance and outlook.

How do we generate the financial health score of Revelation Biosciences Inc?

To generate the financial health score of Revelation Biosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Revelation Biosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Revelation Biosciences Inc.

How do we generate the company valuation score of Revelation Biosciences Inc?

To generate the company valuation score of Revelation Biosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Revelation Biosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Revelation Biosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Revelation Biosciences Inc.

How do we generate the earnings forecast score of Revelation Biosciences Inc?

To calculate the earnings forecast score of Revelation Biosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Revelation Biosciences Inc’s future.

How do we generate the price momentum score of Revelation Biosciences Inc?

When generating the price momentum score for Revelation Biosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Revelation Biosciences Inc’s prices. A higher score indicates a more stable short-term price trend for Revelation Biosciences Inc.

How do we generate the institutional confidence score of Revelation Biosciences Inc?

To generate the institutional confidence score of Revelation Biosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Revelation Biosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Revelation Biosciences Inc.

How do we generate the risk management score of Revelation Biosciences Inc?

To assess the risk management score of Revelation Biosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Revelation Biosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Revelation Biosciences Inc.
KeyAI